&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-07, 18:54

Monsha’at: Day 2 of Biban 2024 raises the bar for Saudi entrepreneurship with over 1.35bn Saudi Riyals worth of agreements launched
Lesley Moroney

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-23, 13:20

Bitget and Foresight Ventures Invest $30 Million in TON Blockchain to Accelerate Growing Telegram-based Projects
Kristofer Henninger

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-27, 10:00

David Barrett, CEO of EBC Financial Group (UK) Ltd and EBC Financial Group (Cayman) Limited, Analyses Global Market Volatility, High-Interest Rate Pressures, and Safe-Haven Investment Strategies Amid 2024 Economic Shifts
Clarita Gooden

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-11, 09:19

President Lula to Speak at FII PRIORITY Rio de Janeiro Summit at the Copacabana Palace Wednesday
Jillian Pearce

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-11, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-11, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
Capemenoneise

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-07, 13:07

Hitachi Energy to invest additional $4.5 billion by 2027 to accelerate the clean energy transition

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-18, 04:07

Unveiling the 8th Future Investment Initiative’s theme: "Infinite Horizons: Investing Today, Shaping Tomorrow"

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-15, 19:00

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-15, 19:00

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

Notified -

Popular Posts